BG Medicine And Abbott To Develop Galectin-3 Test For The I-STAT(R) System
BG Medicine, Inc. announced that it has entered into an agreement with Abbott Laboratories (NYSE: ABT) to extend its current development and commercialization collaboration to include the development of
a galectin-3 test for Abbott Point of Care’s i-STAT® System. Galectin-3 is a novel biomarker that may play a role in detecting the development and progression of heart failure…
Related Articles
No related posts
No related posts
No comments yet. Be the first.
Leave a reply
